Filed Pursuant to Rule 433 of the Securities Act of 1933
Issuer Free Writing Prospectus dated October 5, 2016
Relating to Preliminary Prospectus dated October 4, 2016
Registration No. 333-212511
AZURRX BIOPHARMA, INC.
FREE WRITING PROSPECTUS
This free writing prospectus relates only to, and should be read together with, the preliminary prospectus dated October 4, 2016 (the “Preliminary Prospectus”) included in Amendment No. 6 to the Registration Statement on Form S-1 (File No. 333-212511) (the “Registration Statement”) relating to the initial public offering of common stock of AzurRx BioPharma, Inc. (the “Company”).
On October 4, 2016, we filed Amendment No. 6 to the Registration Statement, which may be accessed through the following link: https://www.sec.gov/Archives/edgar/data/1604191/000165495416002634/0001654954-16-002634-index.htm
The information in this free writing prospectus is preliminary and is subject to completion or change. This free writing prospectus is only a summary of the changes to the Preliminary Prospectus and should be read together with the Preliminary Prospectus included in the Registration Statement, including the section entitled “Risk Factors” beginning on page 6 of the Preliminary Prospectus. Capitalized terms used, but not defined, herein have the meanings set forth in the Preliminary Prospectus. The following information updates and supersedes the information contained in the Preliminary Prospectus to the extent that such information is inconsistent therewith.
AzurRx BioPharma, Inc. has filed a registration statement, including the preliminary prospectus, with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus in that registration statement and other documents we have filed with the SEC for more complete information about us and this offering. You may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, you may obtaincopies of the preliminary prospectus by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 100 Wall Street, Suite 6600, New York, NY 10005, by telephone at 646-998-7605, or by email at cap-mkts@wallachbeth.com, or Network 1 Financial Securities, Inc., Attention: Keith Testaverde, by telephone at 800-886-7007or by mail at 2 Bridge Avenue, Suite 241, Redbank, NJ 07701.
